Vical Incorporated (NASDAQ:VICL) Stock Rating Reaffirmed by Ifs Securities
Vical Incorporated (NASDAQ:VICL)‘s stock had its “outperform” rating restated by research analysts at Ifs Securities in a research note issued to investors on Tuesday.
A number of other research firms have also weighed in on VICL. HC Wainwright set a $9.00 target price on shares of Vical and gave the stock a “buy” rating in a research report on Wednesday. Rodman & Renshaw reissued a “buy” rating and set a $9.00 target price on shares of Vical in a research report on Monday, June 12th.
Shares of Vical (NASDAQ VICL) opened at 2.42 on Tuesday. Vical has a 52 week low of $2.05 and a 52 week high of $4.50. The firm’s market capitalization is $26.95 million. The stock’s 50 day moving average price is $2.61 and its 200 day moving average price is $2.34.
Vical (NASDAQ:VICL) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.02. The firm had revenue of $3.42 million for the quarter, compared to analyst estimates of $3.35 million. Vical had a negative return on equity of 26.09% and a negative net margin of 92.02%. On average, analysts predict that Vical will post ($1.05) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/11/vical-incorporated-nasdaqvicl-stock-rating-reaffirmed-by-ifs-securities.html.
A hedge fund recently raised its stake in Vical stock. Renaissance Technologies LLC raised its position in shares of Vical Incorporated (NASDAQ:VICL) by 6.0% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 416,029 shares of the biotechnology company’s stock after buying an additional 23,520 shares during the period. Renaissance Technologies LLC’s holdings in Vical were worth $932,000 at the end of the most recent reporting period. 23.65% of the stock is owned by institutional investors.
Vical Company Profile
Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.